PDX1 and neoplasm: In vivo, both syngeneic orthotopic and KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre) mouse models with tissue-specific Ulk1 deletion exhibited significant delayed tumor progression, reduced tumor burden and extended survival.